Which biologic do patients prefer?
Rheumatoid arthritis patients are much less likely to discontinue biologic treatment if they are prescribed etanercept, according to a meta-analysis of drug registries.
Data from 100 studies with over 200,000 patients revealed that after three years of biologic therapy, 44% of patients had discontinued treatment.
But the figure was substantially lower for etanercept (35%), compared with infliximab or adalimumab (46%).
Men were less likely to discontinue treatment compared with women, as were